

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): June 30, 2011

CytoDyn Inc.

(Exact Name of Registrant as Specified in its Charter)

Colorado
(State of Incorporation)

000-49908
(Commission
File Number)

75-3056237
(I.R.S. Employer
Identification Number)

110 Crenshaw Lake Road, Lutz, Florida 33548
(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: (813) 527-6969

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Nader Pourhassan, PhD, has accepted the challenge of becoming the new Managing Director of Business Development of CytoDyn Inc. (the "Company"), effective as of June 30, 2011, and will no longer act as the Company's Chief Operating Officer, effective as of June 30, 2011.

Item 7.01. Regulation FD Disclosure

On July 5, 2011, the Company issued a press release announcing Dr. Pourhassan's new position with the Company. The press release is furnished as Exhibit 99.1 to this Current Report. Exhibit 99.1 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and will not be incorporated by reference into any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

The following exhibit is filed herewith:

Exhibit

<u>No.</u>	<u>Description</u>
99.1	Press Release dated July 5, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CytoDyn Inc.

July 5, 2011

By: /s/ Kenneth J. Van Ness

Kenneth J. Van Ness
President and CEO

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated July 5, 2011

PRESS RELEASE**CYTODYN ANNOUNCES NEW ROLE FOR NADER POURHASSAN**

Lutz, Florida, July 5, 2011 – CytoDyn Inc. (the “Company”) (OTC:CYDY.PK) announced that Nader Pourhassan, PhD, has accepted the challenge of becoming the new Managing Director of Business Development of the Company, effective as of June 30, 2011, and will no longer act as the Company’s Chief Operating Officer, effective as of June 30, 2011. The Company is pleased that Dr. Pourhassan’s new focus will be to help advance the development of the Company’s current and future business relationships worldwide. Dr. Pourhassan commented, “After spending approximately three years as the Chief Operating Officer of the Company, the new management and leadership has provided me a platform to expand and develop the Company’s story worldwide.” “No position could be more exciting and challenging, I am looking forward and am very pleased to accept the challenge”, commented Dr. Pourhassan. Dr. Pourhassan accepted this position at the request of Kenneth J. Van Ness, President and Chief Executive Officer of the Company. The Company believes that Dr. Pourhassan will bring his enthusiasm and commitment to the future success of the Company in this challenging position.

Forward Looking Statements

The Press Release includes forward-looking statements and includes forward-looking information within the meaning of United States securities laws. These statements and this information represent the Company’s intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, of which many are beyond the Company’s control. These factors could cause actual results to differ materially from such forward-looking statements or forward-looking information. The words “believe,” “estimate,” “expect,” “intend,” “anticipate,” “foresee,” “plan,” and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or on this forward-looking information.

For more information please contact:

Douglas E. Jacobson
Controller
(813) 527-6969